MedPath

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Phase 2
Terminated
Conditions
Non Arteritic Anterior Ischemic Optic Neuropathy
Interventions
Drug: QPI-1007 Injection - 1.5 mg
Drug: QPI-1007 Injection - 3.0 mg
Other: Sham Injection Procedure
Registration Number
NCT02341560
Lead Sponsor
Quark Pharmaceuticals
Brief Summary

This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population. This study will also evaluate the structural changes in the retina following administration of QPI-1007.

Detailed Description

This is a double masked, randomized, sham-controlled efficacy and safety study that will enroll approximately 800 subjects with recent-onset NAION. Subjects will be randomized into one of 3 groups in a 1:1:1 ratio, and assigned to receive QPI-1007 and/or a sham procedure. Subjects will have a two in three (66%) chance of receiving active treatment (no sham procedure) and a one in three (33%) chance of receiving sham procedure (no active treatment). Total study time involvement is approximately 12 months.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
732
Inclusion Criteria
  • Positive diagnosis of first episode of NAION in the study eye with symptom onset within 14 days prior to planned study drug administration/sham procedure
  • Best corrected visual acuity score in the study eye is better than or equal to 15 letter score, measured using the ETDRS visual acuity protocol at Day 1 prior to study drug administration/sham procedure.
  • Clear ocular media and able to undergo adequate pupil dilation to allow a good fundus examination

Key

Exclusion Criteria
  • Present use or history of any treatment for the current episode of NAION, including systemic steroids, brimonidine, or traditional Chinese herbal medicine
  • Prior episode of NAION in the study eye only
  • Present use of drugs known to cause optic nerve or retinal toxicity at Day 1/Randomization, such as: chloroquine or hydroxychloroquine, ethambutol, Vigabatrin. Subjects who need to be prescribed any of these drugs during the course of the study will be discontinued from the trial.
  • Any medical condition, concomitant therapy, or previous incisional or laser surgery that, in the opinion of the Investigator, would preclude IVT injection in the study eye only
  • Clinical evidence of temporal arteritis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
single dose or multiple doseQPI-1007 Injection - 1.5 mgQPI-1007 Injection - 1.5 mg
single or multiple doseQPI-1007 Injection - 3.0 mgQPI-1007 Injection - 3.0 mg
ShamSham Injection ProcedureSham injection procedure
Primary Outcome Measures
NameTimeMethod
Effect of QPI-1007 as assessed by Best Corrected Visual Acuity (BCVA)Baseline through Month 12
Safety and tolerability of QPI-1007 as assessed by adverse events (AE), laboratory evaluations, ECGs, ophthalmic evaluations, slit lamp anterior/posterior examinations, intraocular pressure measurements, presence/absence of vitreous inflammationBaseline through Month 12
Secondary Outcome Measures
NameTimeMethod
Mean change in BCVA score, as measured by ETDRS visual acuity protocol in the study eyeDay 1 through Month 12
Mean change of Visual Fields, as assessed by Humphrey standard automated perimetryDay 1 through Month 12

Trial Locations

Locations (83)

Rutgers, New Jersey Medical School

🇺🇸

Newark, New Jersey, United States

Loma Linda University Eye Institute

🇺🇸

Loma Linda, California, United States

Datta Meghe Institute of Medical Sciences

🇮🇳

Wardha, India

University of Miami Miller School of Medicine/Bascom Palmer Eye Institute

🇺🇸

Miami, Florida, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

University of Houston, Neuro-Ophth of Texas

🇺🇸

Houston, Texas, United States

Swedish Medical Center, CO/NOCNW

🇺🇸

Seattle, Washington, United States

University of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

Duke University Eye Center

🇺🇸

Durham, North Carolina, United States

Sarasota Retina Institute

🇺🇸

Sarasota, Florida, United States

University of Pennsylvania, Scheie Eye Institute

🇺🇸

Philadelphia, Pennsylvania, United States

NorthShore University Healthsystem

🇺🇸

Glenview, Illinois, United States

Stanford University

🇺🇸

Palo Alto, California, United States

Cleveland Clinic, Cole Eye Institute

🇺🇸

Cleveland, Ohio, United States

Retina Consultants of Charleston

🇺🇸

Charleston, South Carolina, United States

Cornell University School of Medicine

🇺🇸

New York, New York, United States

NeuroEyeOrbit Institute

🇺🇸

Los Angeles, California, United States

University of Illinois at Chicago, Department of Ophthalmology (MC 648)

🇺🇸

Chicago, Illinois, United States

Boston Medical Center

🇺🇸

Boston, Massachusetts, United States

Cape Coral Eye Center

🇺🇸

Cape Coral, Florida, United States

ICARE Research Centre and Post Graduate Institute

🇮🇳

Noida, Uttar Pradesh, India

Tan Tock Seng Hospital, Department of Ophthalmology

🇸🇬

Singapore, Singapore

State University of New York at Stony Brook

🇺🇸

Stony Brook, New York, United States

Raleigh Neurology Associates

🇺🇸

Raleigh, North Carolina, United States

Dr. Rajendra Prasad Centre for Ophthalmic Sciences, A.I.I.M.S.

🇮🇳

New Delhi, India

Bnai Zion Medical Center

🇮🇱

Haifa, Israel

Soroka University Medical Center

🇮🇱

Beer-Sheva, Israel

Rabin Medical Center, Belinson Campus

🇮🇱

Petach-Tikva, Israel

The Eye Care Group

🇺🇸

Waterbury, Connecticut, United States

Royal Perth Hospital

🇦🇺

Perth, Western Australia, Australia

Massachusetts Eye and Ear Infirmary

🇺🇸

Boston, Massachusetts, United States

Washington University in St. Louis

🇺🇸

Saint Louis, Missouri, United States

Beijing Tongren Hospital, Capital Medical University

🇨🇳

Beijing, China

Foresight Studies

🇺🇸

San Antonio, Texas, United States

Sankara Nethralaya (Vision Research Foundation)

🇮🇳

Chennai, Tami Nadu, India

AOU Policlinico S. Orsola-Malpighi

🇮🇹

Bologna, Italy

Kaplan Medical Center

🇮🇱

Rehovot, Israel

Hadassah Medical Center

🇮🇱

Jerusalem, Yerushalayim, Israel

PBMA'S H. V. Desai Eye Hospital

🇮🇳

Pune, Maharashtra, India

Scientific Institute Auxologico Italiano

🇮🇹

Milano, Italy

Singapore National Eye Centre

🇸🇬

Singapore, Singapore

AOU Careggi

🇮🇹

Firenze, Italy

The Chaim Sheba Medical Center

🇮🇱

Tel-Hashomer, Israel

The Second Xiangya Hospital of Central South University

🇨🇳

Changsha, Hunan, China

Peking University Eye Center, The Third Hospital Peking University.

🇨🇳

Beijing, China

Peking Union Medical College Hospital

🇨🇳

Beijing, China

Tianjin Eye Hospital

🇨🇳

Tianjin, China

Aravind Eye Hospital

🇮🇳

Madurai, Tamil Nadu, India

University of Southern California

🇺🇸

Los Angeles, California, United States

University of Utah John A. Moran Eye Center

🇺🇸

Salt Lake City, Utah, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Dean McGee Eye Institute

🇺🇸

Oklahoma City, Oklahoma, United States

Universitäts-Augenklinik Tübingen

🇩🇪

Tubingen, Germany

The Tel-Aviv Sourasky Medical Center

🇮🇱

Tel-Aviv, Israel

Bethesda Neurology, LLC

🇺🇸

Bethesda, Maryland, United States

University of Colorado Denver, Department of Neurology

🇺🇸

Aurora, Colorado, United States

University of Nebraska Medical Center and Truhlsen Eye Institute

🇺🇸

Omaha, Nebraska, United States

University of Arkansas Medical Center, Jones Eye Institute

🇺🇸

Little Rock, Arkansas, United States

Unversity of California, Los Angeles (UCLA)

🇺🇸

Pasadena, California, United States

Greater Baltimore Medical Center

🇺🇸

Baltimore, Maryland, United States

University of Kentucky, Department of Neurology

🇺🇸

Lexington, Kentucky, United States

New York Eye and Ear Infirmary of Mount Sinai

🇺🇸

New York, New York, United States

University of Rochester, Flaum Eye Institute

🇺🇸

Rochester, New York, United States

University of Virginia Health Sciences Center

🇺🇸

Charlottesville, Virginia, United States

L V Prasad Eye Institute

🇮🇳

Bhubaneswar, Orissa, India

Universitätsklinikum Münster

🇩🇪

Münster, Germany

Narayana Nethralaya

🇮🇳

Bangalore, Karnataka,, India

Sri Sankaradeva Nethralaya

🇮🇳

Guwahati, Assam, India

Sanjay Gandhi Postgraduate Institute of Medical Sciences

🇮🇳

Lucknow, Uttar Pradesh, India

Scientific institute San Raffaele

🇮🇹

Milano, Italy

University Eye Clinic

🇮🇹

Parma, Italy

Houston Methodist Hospital, Blanton Eye Institute

🇺🇸

Houston, Texas, United States

Retina Consultants of Southern Colorado, PC

🇺🇸

Colorado Springs, Colorado, United States

University of Michigan

🇺🇸

Ann Arbor, Michigan, United States

SUNY Upstate Medical University

🇺🇸

Syracuse, New York, United States

Vision South Australia

🇦🇺

Kent Town, South Australia, Australia

University of Washington Department of Ophthalmology

🇺🇸

Seattle, Washington, United States

Universitätsklinikum Regensburg-Klinik und Poliklinik für Augenheilkunde

🇩🇪

Regensburg, Germany

Sydney Eye Hospital/Save Sight Institute

🇦🇺

Sydney, New South Wales, Australia

Universitätsklinikum Carl Gustav Carus-Dresden-Klinik und Poliklinik für Augenheilkunde

🇩🇪

Dresden, Germany

The Royal Victorian Eye and Ear Hospital

🇦🇺

Fitzroy, Victoria, Australia

Universitätsklinikum Aachen-Augenklinik

🇩🇪

Aachen, Germany

Universitätsmedizin d. Johannes Gutenberg-Universität Mainz

🇩🇪

Mainz, Rheinland-Pfalz, Germany

© Copyright 2025. All Rights Reserved by MedPath